166 results about "Mouse tumor" patented technology

The invention provides nano-particles for generating CAR-T in vivo and application of the nano-particles, and belongs to the technical field of medical preparations. The nanoparticles are nanoparticles which are coupled with a CD7 antibody and entrapped with mRNA (messenger Ribonucleic Acid); the mRNA is obtained by transcription of a target gene; the target gene comprises a TROP2 single-chain antibody; the nucleotide sequence of the TROP2 single-chain antibody is as shown in SEQ ID NO: 1. The nucleotide sequence of the TROP2 single-chain antibody is optimized, the CAR containing the TROP2 single-chain antibody is constructed, then the CAR is transcribed to obtain mRNA, LNP entrapped with mRNA is prepared, then the CD7 antibody subjected to amino acid sequence optimization is adopted to be coupled with the LNP entrapped with mRNA, the transfection efficiency of the CD7 antibody in T cells is high, the CD7 antibody is injected into a mouse tumor model, and the lifetime of mice can be prolonged; t cells transfected by the T cell transfecting agent have high killing efficiency on HELA cells and LOVO cells.

The invention discloses a traditional Chinese medicine composition for treating breast cancer complicated with anxiety disorder as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is mainly prepared from the following raw material medicines: astragalus membranaceus, herba epimedii, ligusticum wallichii, semen boitae, acanthopanax, rhizoma drynariae, selfheal, arisaema cum bile, turtle shell, nigrum fruit, salvia chinensis and artemisia apiacea. The invention further discloses a preparation method of the traditional Chinese medicine composition, a pharmaceutical preparation and application. Pharmacodynamic experiments prove that the traditional Chinese medicine composition can remarkably inhibit tumor growth of anxiety tumor-bearing mice and improve anxiety behavioral indexes, achieves dual treatment targets of tumor resistance and emotion regulation, and is particularly suitable for middle and advanced breast cancer combined anxiety patient groups needing long-term treatment.

The invention belongs to the field of biological medicine, and particularly relates to an information rhzomorph array for resisting small cell lung cancer and application of the information rhzomorph array. The invention provides polypeptides with amino acid sequences as shown in SEQ ID NO: 1-30. The invention also provides a medicine for resisting small cell lung cancer. The medicine comprises fusion protein obtained by respectively connecting the channel structural domain of the coliform and the polypeptide with the amino acid sequence shown as SEQ ID NO: 1-30. Pharmacodynamic experiments prove that in each growth cycle, a mouse tumor-bearing model always cannot get rid of the recognition and killing of an information rhzomorph array composed of thirty fusion proteins on tumors. A guinea pig model experiment proves that no toxic or side effect is generated in an animal model when the information rhzomorph array is continuously used for 30 days. The information rhzomorph array can be used as an effective small cell lung cancer treatment medicine.

The invention discloses application of combination of okannin and epirubicin in prevention and / or treatment of colon cancer, relates to the technical field of biological medicine, and is technically characterized in that a pharmaceutical composition comprises okannin and epirubicin, the preferable molar ratio is 15: 1 or 7.5: 1, and the pharmaceutical composition aims to reduce the dosage of epirubicin, reduce toxic and side effects and enhance the curative effect through a synergistic effect. The invention also comprises a method for detecting the influence of the pharmaceutical composition on colon cancer cell viability and apoptosis, and an animal model for evaluating the influence on the tumor growth of a colon cancer tumor-bearing mouse. The pharmaceutical composition disclosed by the invention can be used for remarkably inhibiting the proliferation of colon cancer cells and enhancing the apoptosis promoting effect of epirubicin, and shows a good anti-tumor effect and relatively low visceral organ toxicity in an animal model. The invention provides a safe and effective new treatment strategy for colon cancer patients.

Disclosed are compositions, kits, and methods for identifying genes that are involved in T-cell trafficking. In particular, the compositions, kits, and methods may be used to identify genes involved in T-cell trafficking and / or infiltration into tumors such as genes that encode immune checkpoint regulators and / or stimulatory agents. The disclosed compositions, kits, and methods utilize the Sleeping Beauty® transposon system in a mouse tumor model to identify genes that are involved in T-cell trafficking and infiltration into tumors. The genes identified in the disclosed methods may provide immunotherapy targets in the tumor microenvironment. The identified genes may be utilized in order to develop therapies that enhance T-cell trafficking and infiltration into tumors and / or T-cell killing of tumors such as in chimeric antigen receptor (CAR) T cell therapies.

The invention belongs to the technical field of anti-tumor, and discloses application of HP and ICT combined anti-PD-1 inhibitor hydrogel in residual cancer recurrence after IRFA. The excellent drug delivery capacity of the hydrogel system is utilized, and the in-vivo local slow release effect of ICT and BMS202 can be remarkably amplified. Through synergistic treatment of the TAN and the MDSC, local and whole body adaptive immunoreactions can be efficiently activated, TAN is effectively reprogrammed to be in a tumor suppression type, infiltration of PMN-MDSC is reduced, and the conclusion is verified in a plurality of mouse tumor models in the chapter. Therefore, the HP (at) ICT / BMS provides a promising delivery strategy for improving the sensitivity of anti-PD-L1 treatment and efficiently preventing and treating latent residual cancer and metastasis after IRFA operation.

The invention discloses a construction method of a tumor-associated meningeal metastasis model, and particularly relates to the technical field of biology. The method comprises the following steps: treating tumor cells according to a cell passage mode and centrifugal parameters, adding a serum-free culture medium, centrifuging again, adjusting the cell density by using a serum-free fresh culture medium, and sub-packaging to obtain a tumor cell suspension; the tumor cell suspension is injected into the L4-L5 intervertebral space of the mouse. After injection, the mouse resuscitates and normally diets; the growth of the tumor is monitored through a small animal living body imaging technology, and the dissected organ is subjected to in-vitro imaging to judge the invasion range of the tumor. The mouse tumor meningeal metastasis model is constructed in a simple, repeatable and efficient manner.

Provided is an antibody fusion protein, which simultaneously targets CD24, IL4R and an integrin receptor. An in-vitro assay shows that the antibody fusion protein significantly inhibits the proliferation, migration, invasion, colony formation and adhesion of renal cancer cells, also has a comprehensive and significant anti-tumor effect on gastric cancer, colon cancer and breast cancer, and has the effect of inhibiting angiogenesis. The results of a mouse tumor model of subcutaneous transplantation of MC38-hPDL1C57BL6 / J show that the antibody fusion protein combined with the PDL1 antagonist atezolizumab can significantly inhibit tumor growth. The antibody fusion protein can be used as a potential candidate drug for treating metastatic renal cell carcinoma, PDL1-overexpressing cancer, ophthalmic diseases and inflammation or autoimmune diseases.

The invention belongs to the technical field of preparation of cancer drugs, and particularly relates to application of a compound or salt thereof in preparation of cancer treatment drugs, the structure of the compound is shown in the formula I. The compound shown in the formula I can remarkably inhibit growth of tumors (such as breast cancer), and compared with a blank control group and mice treated by the compound shown in the formula I, the tumors grow more slowly and are smaller, and the cancer treatment effect is better. The material is lighter, and the life cycle is obviously prolonged; in addition, the compound shown in the formula I can be combined with Anti-PD1 to synergistically enhance the tumor inhibition effect.

The present application relates to a kind of anaphalis contorta exosome extraction method and its application.The exosome is obtained by ultra-high speed centrifugation method from fresh anaphalis contorta, particle size is 160-200 nm, Zeta potential is-21.63±1.34 mV, with double membrane structure, mainly containing protein (such as resveratrol O-methyltransferase etc.) and phospholipid, polysaccharide content is only 12.5% of anaphalis contorta fresh medicine, and does not contain traditional active ingredient anaphalis contorta glycoside.Experiments show that anaphalis contorta exosome can be targeted to enrich in colorectal tissue, significantly improve AOM / DSS induced colorectal cancer model mouse tumor microenvironment, reduce tumor number, regulate T cell and macrophage ratio, and relieve pathological damage, better than anaphalis contorta fresh medicine.The mechanism is related to protein component, not polysaccharide or small molecule component.The anaphalis contorta exosome provided in the present application has simple preparation process, high safety, and has significant anti-colorectal cancer application potential.

Provided is use of a KIF18A inhibitor in preparing a medicament for treating ovarian cancer disease. Pharmacological studies have demonstrated that compounds 1-3 can inhibit the growth of ovarian cancer heterogeneous tumors, and a high dose of the compounds can cause tumor regression in mice. Compared with AMG650, a lower drug exposure of compounds 1-3 reduces the potential drug accumulation toxicity and possesses a significant therapeutic effect on ovarian cancer with good safety.

Provided are an anti-DLL3 antibody or an antigen-binding fragment thereof, a chimeric antigen receptor and a mutant thereof, and an enhanced chimeric antigen receptor comprising a PDL1 antagonist and an mIL7 element. Further provided are a nucleic acid encoding same, an expression cassette, vector and cell comprising the nucleic acid, a preparation method, and a use for preventing, treating, detecting, or diagnosing diseases related to DLL3. In the enhanced DLL3 chimeric antigen receptor, the PDL1 antagonist and the cell membrane IL7 cytokine element play a critical role in a long-term anti-tumor process. Animal efficacy experiments have shown complete tumor regression in all mice, indicating broad application prospects in the pharmaceutical field.

The invention provides a method for treating multiple myeloma in subcutaneous and in-situ tumor models by using C3G. The method comprises the following steps: S1, testing the effect of C3G on tumor growth of an MM model mouse; s2, testing the effect of C3G on the activity, cell cycle and cell proliferation of an MM cell line; s3, testing the effect of C3G on MM cell apoptosis; s4, testing the effect of C3G on NAD < + > secretion and MM cell apoptosis; s5, the effect of C3G on Sirt1 expression and NF-kB acetylation of the MM cells is tested; s6, proving an acetylation regulation mechanism of the C3G to the NF-kappa B; the natural compound C3G is used as a novel therapy for clinically treating multiple myeloma, the C3G has the advantages of low cost, no side effect and the like, and researches prove that the C3G shows a remarkable inhibition effect on MM cells, which means that the C3G has clinical feasibility in the aspect of treating MM, and when the C3G is combined with a CD38 monoclonal antibody, such as dartumumab, not only is the curative effect of the monoclonal antibody not affected, but also the curative effect of the CD38 monoclonal antibody is not affected, and the C3G has a remarkable inhibition effect on the MM cells. And on the contrary, a synergistic effect is possibly generated, and the effect of treating the MM is remarkably enhanced.

The present invention provides novel human fms related tyrosine kinase 3 (FLT3) antigen binding proteins, such as antibodies, having improved FLT3 binding affinity, and / or anti-tumor activity. The FLT3 antibodies of the invention were generated by mutation of a parent FLT3 antibody and tested in in vitro in binding assays as well as in vivo in a mouse tumor model and in human patient tumor samples. The antibodies of the invention are provided as monospecific constructs or in a bispecific FLT3xCD3 antibody format and show excellent target affinity and / or tumor cell killing. The present invention also relates methods for producing the antigen binding proteins of the invention as well as nucleic acids encoding them, vectors for and host cells for their expression. The invention further relates to methods of treating or diagnosing a disease such as leukemia using an FLT3 antigen binding protein (ABP) of the invention.

The invention relates to application of (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium in preparation of anti-cancer drugs, and belongs to the technical field of medical application, the structure of (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium is as shown in the following formula I, the (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium can inhibit the growth of gastric cancer cells, inhibit the proliferation, invasion and migration of the gastric cancer cells by promoting the autophagy and mitochondrial rupture of AGS and HGC-27 cells of the gastric cancer cells, and block the gastric cancer cells in the G1 stage. Furthermore, in-vivo experiments of mice prove that ZWK-3 can inhibit tumor growth of the mice, shows obvious dose dependence, and does not influence the body weight and visceral indexes of the mice at the same time. Formula I.

This invention belongs to the field of cancer drug preparation technology, specifically relating to the use of compounds or their salts in the preparation of cancer therapeutic drugs. The structure of the compound is shown in Formula I. The compound shown in Formula I can significantly inhibit tumor (e.g., breast cancer) growth. Compared with the blank control group, the tumors of mice treated with the compound shown in Formula I grow more slowly, are smaller and lighter, and have a significantly longer survival period. In addition, the compound shown in Formula I can be used in combination with Anti-PD1 to synergistically enhance the tumor inhibition effect.

The invention belongs to the technical field of biological medicines, and particularly relates to application of MIM2 and derivatives thereof in preparation of products for treating tissue fibrosis. It is found that the compound MIM2 can effectively inhibit expression and synthesis of various cancers (extracellular matrix proteins such as collagen and laminin in cells). In-vitro experiments show that after MIM2 treatment, collagen and laminin expression of the cancer cells, skin fibroblasts, hepatic stellate cells and embryonic lung cells is remarkably reduced. Animal experiments further prove that the MIM2 can effectively inhibit collagen deposition in tumor tissues of tumor-bearing mice, can slow down the fibrosis process of liver fibrosis and pulmonary fibrosis mouse models, and can reduce the level of plasma hyaluronic acid at the same time. The results show that the MIM2 has the effects of inhibiting extracellular matrix deposition and delaying tissue fibrosis, and is expected to be developed into small molecular drugs for treating cancer-related fibrosis and other fibrosis diseases.

The invention belongs to the technical field of tumor drugs, and provides application of timosaponin A1 in treatment of colorectal cancer, and the application is that timosaponin A1 is applied to preparation of drugs for treating colorectal cancer. The inhibition effect of timosaponin A1 on mitochondrial activity in colorectal cancer cells is evaluated through in-vitro cell experiments, two mouse tumor models, multi-omics analysis and other methods; results show that timosaponin A1 can stabilize a DHRS4-LONP2-TFAM compound in vivo and in vitro, so that TFAM degradation is promoted, mitochondrial biogenesis is inhibited, tumor cell growth is inhibited, and the aim of treating colorectal cancer is achieved.

This invention belongs to the medical field and establishes a clinically relevant mouse glioblastoma treatment model, obtaining "cured" mice. When these "cured" mice were re-challenged with tumors, the tumors spontaneously regressed, and the animals achieved long-term survival. This indicates that the "cured" mice acquired immunity to the tumor, and these mice are named "cured-immune" mice. Intracranial inoculation of tumor cells into the "cured-immune" mice specifically induced a microglia subset exhibiting high expression of the purinergic receptor P2ry12 gene. High ) and immune-boosting functional characteristics, P2ry12 infusion Hi Small glial subsets significantly prolonged the survival time of glioma-bearing mice. Compared with the control group, P2ry12 in "cured-immune" (LTS) mice was significantly reduced. High Ccl12 low Differentially expressed genes in microglial cell subsets are enriched in signaling pathways that promote immune function, hence P2ry12 High Ccl12 low Microglial cell subsets have therapeutic effects on gliomas.

The invention belongs to the technical field of medicines, and generally relates to application of N-acetyl-L-tyrosine and an N-acetyltransferase strain for expressing tyrosine in preparation of tumor treatment drugs or anti-tumor immune activation drugs for elderly individuals. Researches find that N-acetyl-L-tyrosine and a tyrosine-expressing N-acetyltransferase strain can significantly inhibit mouse tumors, which shows that the mouse tumors grow slowly or the number of the mouse tumors is reduced. The N-acetyl-L-tyrosine can also regulate anti-tumor immunity, and is expressed as promoting TCF1 expression and increasing the proportion of depleted precursor T cells. In the elderly, the curative effect is particularly prominent. The results show that N-acetyl-L-tyrosine and related strains thereof can be used for tumor treatment and anti-tumor immune aging regulation.

The invention discloses a mouse gastric adenocarcinoma cell line MPC as well as a construction method and application thereof, and belongs to the technical field of preparation of tumor cell lines and tumor models. The mouse gastric adenocarcinoma cell strain MPC is preserved in China Center for Type Culture Collection, has Cdh1 and Tp53 gene mutations at the same time, has stable cell biological characteristics and typical adenocarcinoma characteristics, can form tumors in immunodeficient and normal immune mice, can be used for preparing a mouse tumor model for occurrence, development and metastasis of gastric cancer, and has a good application prospect. The method is applied to important researches such as molecular biology, cytobiology, detection kit development, new drug research and development and the like.

The invention discloses application of an LPIN1 inhibitor in preparation of drugs for treating FLT3-ITD mutant acute myelogenous leukemia, reducing tumor load of a patient with the FLT3-ITD mutant acute myelogenous leukemia, improving the survival rate of the patient with the FLT3-ITD mutant acute myelogenous leukemia and / or reducing the proliferation activity of primary cells of the patient with the FLT3-ITD mutant acute myelogenous leukemia. The LPIN1 inhibitor for inhibiting lipid metabolism related enzyme LPIN1 can significantly induce apoptosis of FLT3-ITD mutant AML cells, has limited influence on non-mutant AML cells, and has mutation specificity. More importantly, the LPIN1 inhibitor (such as propranolol) and the FLT3 inhibitor (such as quinatinib) are combined for use, so that a synergistic anti-leukemia effect can be generated, and a remarkable anti-tumor effect is shown in vitro and in a mouse transplantation tumor model, so that the LPIN1 inhibitor and the FLT3 inhibitor have a good application prospect.

The preparation method of the fluorescent probe (S) comprises the following steps: adding absolute ethyl alcohol into p-phenylenediamine, refluxing and dissolving the solution (solution A) while heating at 80 DEG C, dissolving salicylaldehyde into a proper amount of absolute ethyl alcohol (solution B), dropwise adding the solution B into the solution A, and stirring to obtain a mixed solution; heating reflux is kept at 80 DEG C in the whole process, stirring is continuously carried out, and after reflux is carried out for 2 hours, filtering is carried out to obtain a faint yellow solid, namely the fluorescent probe (S). The fluorescent probe can specifically recognize hydrogen sulfide (H2S) under the interference of common ions, is strong in anti-interference capability and high in sensitivity, and can be used for real-time monitoring and fluorescence imaging of endogenous H2S of cells and mouse tumors.

The invention discloses a nano drug delivery system for targeting immune cells. Comprising core nanoparticles formed by a polylactic acid-glycolic acid copolymer and used for encapsulating a therapeutic drug; the polyethylene glycol functional layer is coated on the surface of the core, so that the blood circulation time is prolonged; the targeting ligand is covalently connected to the polyethylene glycol layer, is a high-affinity ligand for specifically recognizing an immune cell surface receptor, and comprises an anti-DEC205 single-chain antibody fragment and a mannose or anti-CD3 antibody fragment. The innovation point is that the binding affinity of the targeting ligand to specific receptors on the surfaces of dendritic cells, macrophages or T cells is obviously higher than that of a conventional ligand, and efficient intracellular delivery is realized through a synergistic structure of a polylactic acid-glycolic acid copolymer-polyethylene glycol-ligand. The technical effects comprise that the in-vitro target immune cell uptake efficiency is greatly improved, the tumor tissue drug enrichment degree of a tumor-bearing mouse is multiplied compared with that of a non-targeted carrier, and the antigen presentation and T cell activation capability is remarkably enhanced.

The invention relates to the technical field of biological medicine, and discloses a lentiviral vector for specifically targeting a target cell and a construction method and application thereof, the lentiviral vector comprises: (1) an antigen targeting artificial protein receptor, the receptor comprising a target cell surface antigen binding domain and a transmembrane domain; (2) a mutated Moreton vesicular disease virus envelope protein; and (3) an expression cassette, wherein the expression cassette comprises a heterologous transgene. The novel lentiviral vector based on the mutated Moreton vesicular disease virus envelope, provided by the invention, can realize specific infection on target cells in vitro and in vivo, and compared with a vesicular stomatitis virus envelope VSV-G, the lentiviral vector constructed based on mutated Moreton vesicular disease virus envelope protein is better in stability in serum, and has a good application prospect. The efficiency of specifically infecting target cells is higher, and the drug effect in a mouse tumor model is more prominent.

The present invention discloses an application of a Toxoplasma fungus in an anti-tumor drug. The Toxoplasma fungus has been deposited in the "China Center for Type Culture Collection" on April 20, 2023, with a deposit number of CCTCCM2023568. The present invention extracts the mycelium of the Toxoplasma fungus, and uses a mouse transplant tumor model experiment to find that the mycelium of the Toxoplasma fungus can effectively inhibit the growth of tumor cells through oral administration. Long-term use has no obvious toxicity to various organs, and can be used to prepare anti-tumor drugs, etc., with good anti-tumor effects.

The invention provides an anti-tumor combined treatment method for improving a radiotherapy curative effect by using nintedanib, and relates to the technical field of tumor treatment. The anti-tumor combined treatment method comprises the following steps: selecting a male mouse or a male nude mouse as an experimental animal, and subcutaneously constructing a tumor-bearing mouse model on the back of the experimental animal; when the tumor volume of the tumor-bearing mice reaches 70-100mm < 3 >, randomly dividing the tumor-bearing mice into four groups, namely a control group, a nintedanib single drug group, a radiotherapy group and a combined group; measuring the subcutaneous tumor volume and weight of the tumor-bearing mouse every three days; drawing a mouse tumor growth curve, a mouse survival curve and a mouse weight change curve according to the measured data; a tumor-bearing mouse is subjected to living body imaging, tumor tissue paraffin embedding, immunohistochemical staining, TUNEL staining and Hamp; and E, carrying out section staining and blood biochemical detection, and carrying out data analysis by utilizing corresponding analysis software, so as to evaluate the anti-tumor effect and safety of the combined treatment. According to the invention, tumor growth can be effectively inhibited.

The invention belongs to the technical field of biological medicine and food, and particularly discloses a traditional Chinese medicine composition with an auxiliary function on colorectal cancer immunotherapy and application of the traditional Chinese medicine composition, and the composition is prepared from the following components in parts by weight: 1-4 parts of turmeric extract, 1-2 parts of poria cocos extract and 1-2 parts of ginseng extract. The composition prepared by compounding and matching the turmeric extract, the ginseng extract and the poria cocos extract can induce activation of anti-tumor immune response in colorectal cancer tumors in a mouse tumor-bearing model, reverse an immunosuppressive microenvironment and promote response and efficacy exertion of an ICB therapy. Animal model tests prove that the composition has a remarkable synergistic effect on colorectal cancer immunotherapy; the composition disclosed by the invention is mild and stable in property, and can be effectively applied to preparation of medicinal and edible products.

The present invention provides a curcuminol derivative for treating tumors and a preparation method and application thereof, which belongs to the field of medical technology. The present invention obtains a curcuminol derivative, HCL-23, for the first time by structurally modifying curcuminol. The test results show that HCL-23 inhibits cancer cell proliferation by inducing G2 phase cycle arrest, apoptosis and ferroptosis of cancer cells, and can inhibit cancer cell metastasis. In vivo tests show that HCL-23 can inhibit the growth of tumor volume in tumor-bearing mice, reduce the tumor volume and weight of tumor-bearing mice, and thus play an anti-tumor role. The curcuminol derivative HCL-23 of the present invention provides a new idea for the treatment of tumors, especially the research and development of breast cancer drugs.

The present invention provides novel human fms-related tyrosine kinase 3 (FLT3) antigen-binding proteins, such as antibodies, with improved FLT3 binding affinity and / or anti-tumor activity. The FLT3 antibodies of the present invention are generated by mutation of parental FLT3 antibodies and are tested in vitro in binding assays and in vivo in murine tumor models and human patient tumor samples. The antibodies of the present invention are provided in monospecific constructs or bispecific FLT3xCD3 antibody forms and exhibit excellent target affinity and / or tumor cell killing. The present invention also relates to methods for generating the antigen-binding proteins of the present invention, as well as nucleic acids encoding them, vectors expressing them, and host cells. The present invention further relates to methods of using the FLT3 antigen-binding proteins (ABPs) of the present invention for treating or diagnosing diseases such as leukemia.